Primatene OTC Asthma Inhaler Amended NDA Expected Second Quarter
This article was originally published in The Tan Sheet
Amphastar Pharmaceuticals "recently received constructive comments from the FDA regarding our studies" and is "in the process of completing what we believe to be our final human factors study" before responding to a complete response letter the agency submitted in 2014, says company President Jason Shandell.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Appropriations Committee’s report with Agriculture, Rural Development, FDA and Related Agencies FY2021 budget bill also reiterated concern about adding acetaminophen dosing information for children to OTC monograph. But its mentions of FDA initiative to expand ingredients available OTC and homeopathic market oversight were firsts.